The role of a recently discovered peptide—irisin—in physiological and pathological processes

[1] Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481: 463–468. BoströmP WuJ JedrychowskiMP KordeA YeL LoJC RasbachKA BoströmEA ChoiJH LongJZ A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis Nature 2012 481 463 468 10.1038/nature10777352209822237023 Search in Google Scholar

[2] Kurdiova T, Balaz M, Mayer A, Maderova D, Belan V, Wolfrum C, Ukropec J, Ukropcova B. Exercise-mimicking treatment fails to increase Fndc5 mRNA & irisin secretion in primary human myotubes. Peptides. 2014; 56: 1–7. KurdiovaT BalazM MayerA MaderovaD BelanV WolfrumC UkropecJ UkropcovaB Exercise-mimicking treatment fails to increase Fndc5 mRNA & irisin secretion in primary human myotubes Peptides 2014 56 1 7 10.1016/j.peptides.2014.03.00324642356 Search in Google Scholar

[3] Raschke S, Elsen M, Gassenhuber H, Sommerfeld M, Schwahn U, Brockmann B, Jung R, Wisløff U, Tjønna AE, Raastad T, et al. Evidence against a beneficial effect of irisin in humans. PLoS One, 2013; 8: e73680. RaschkeS ElsenM GassenhuberH SommerfeldM SchwahnU BrockmannB JungR WisløffU TjønnaAE RaastadT Evidence against a beneficial effect of irisin in humans PLoS One 2013 8 e73680 10.1371/journal.pone.0073680377067724040023 Search in Google Scholar

[4] Chen N, Li Q, Liu J, Jia S. Irisin, an exercise-induced myokine as a metabolic regulator: An updated narrative review. Diabetes Metab Res Rev. 2016; 32: 51–59. ChenN LiQ LiuJ JiaS Irisin, an exercise-induced myokine as a metabolic regulator: An updated narrative review Diabetes Metab Res Rev 2016 32 51 59 10.1002/dmrr.266025952527 Search in Google Scholar

[5] Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61: 1725–1738. HuhJY PanagiotouG MougiosV BrinkoetterM VamviniMT SchneiderBE MantzorosCS FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise Metabolism 2012 61 1725 1738 10.1016/j.metabol.2012.09.002361441723018146 Search in Google Scholar

[6] Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Cakmak T, Albayrak S, Gungor S, Colakoglu N, Ozercan IH. A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides. 2014; 61: 130–136. AydinS KulogluT AydinS KalayciM YilmazM CakmakT AlbayrakS GungorS ColakogluN OzercanIH A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues Peptides 2014 61 130 136 10.1016/j.peptides.2014.09.01425261800 Search in Google Scholar

[7] Aydin S, Aydin S, Kobat MA, Kalayci M, Eren MN, Yilmaz M, Kuloglu T, Gul E, Secen O, Alatas OD, Baydas A. Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology. Peptides. 2014; 56: 141–145. AydinS AydinS KobatMA KalayciM ErenMN YilmazM KulogluT GulE SecenO AlatasOD BaydasA Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology Peptides 2014 56 141 145 10.1016/j.peptides.2014.04.00224747283 Search in Google Scholar

[8] Piya MK, Harte AL, Sivakumar K, Tripathi G, Voyias PD, James S, Sabico S, Al-Daghri NM, Saravanan P, Barber TM, Kumar S, Vatish M, McTernan PG. The identification of irisin in human cerebrospinal fluid: Influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab. 2014; 306: E512–E518. PiyaMK HarteAL SivakumarK TripathiG VoyiasPD JamesS SabicoS Al-DaghriNM SaravananP BarberTM KumarS VatishM McTernanPG The identification of irisin in human cerebrospinal fluid: Influence of adiposity, metabolic markers, and gestational diabetes Am J Physiol Endocrinol Metab 2014 306 E512 E518 10.1152/ajpendo.00308.201324398403 Search in Google Scholar

[9] Pinkowska A, Podhorska-Okołów M, Dzięgiel P, Nowińska K. The role of irisin in cancer disease. Cells. 2021; 10: 1479. PinkowskaA Podhorska-OkołówM DzięgielP NowińskaK The role of irisin in cancer disease Cells 2021 10 1479 10.3390/cells10061479823111734204674 Search in Google Scholar

[10] Kim H, Wrann CD, Jedrychowski M, Vidoni S, Kitase Y, Nagano K, Zhou C, Chou J, Parkman VA, Novick SJ, et al. Irisin mediates effects on bone and fat via αV integrin receptors. Cell. 2018; 175: 1756–1768. KimH WrannCD JedrychowskiM VidoniS KitaseY NaganoK ZhouC ChouJ ParkmanVA NovickSJ Irisin mediates effects on bone and fat via αV integrin receptors Cell 2018 175 1756 1768 10.1016/j.cell.2018.10.025629804030550785 Search in Google Scholar

[11] Oguri Y, Shinoda K, Kim H, Alba DL, Bolus WR, Wang Q, Brown Z, Pradhan RN, Tajima K, Yoneshiro T, et al. CD81 controls beige fat progenitor cell growth and energy balance via FAK signaling. Cell. 2020; 182: 563–577. OguriY ShinodaK KimH AlbaDL BolusWR WangQ BrownZ PradhanRN TajimaK YoneshiroT CD81 controls beige fat progenitor cell growth and energy balance via FAK signaling Cell 2020 182 563 577 10.1016/j.cell.2020.06.021741567732615086 Search in Google Scholar

[12] Bi J, Zhang J, Ren Y, Du Z, Li T, Wang T, Zhang L, Wang M, Wu Z, Lv Y, Wu R. Irisin reverses intestinal epithelial barrier dysfunction during intestinal injury via binding to the integrin αVβ5 receptor. J Cell Mol Med. 2020; 24: 996–1009. BiJ ZhangJ RenY DuZ LiT WangT ZhangL WangM WuZ LvY WuR Irisin reverses intestinal epithelial barrier dysfunction during intestinal injury via binding to the integrin αVβ5 receptor J Cell Mol Med 2020 24 996 1009 10.1111/jcmm.14811693338431701659 Search in Google Scholar

[13] Park EJ, Myint PK, Ito A, Appiah MG, Darkwah S, Kawamoto E, Shimaoka M. Integrin-ligand interactions in inflammation, cancer, and metabolic disease: Insights into the multifaceted roles of an emerging ligand irisin. Front Cell Dev Biol. 2020; 8: 588066. ParkEJ MyintPK ItoA AppiahMG DarkwahS KawamotoE ShimaokaM Integrin-ligand interactions in inflammation, cancer, and metabolic disease: Insights into the multifaceted roles of an emerging ligand irisin Front Cell Dev Biol 2020 8 588066 10.3389/fcell.2020.588066764975733195249 Search in Google Scholar

[14] Pukajło K, Kolackov K, Łaczmański Ł, Daroszewski J. Irisin – a new mediator of energy homeostasis. Postepy Hig Med Dosw. 2015; 69: 233–242. PukajłoK KolackovK ŁaczmańskiŁ DaroszewskiJ Irisin – a new mediator of energy homeostasis Postepy Hig Med Dosw 2015 69 233 242 10.5604/17322693.114109725720610 Search in Google Scholar

[15] Spiegelman BM. Banting Lecture 2012: Regulation of adipogenesis: Toward new therapeutics for metabolic disease. Diabetes. 2013; 62: 1774–1782. SpiegelmanBM Banting Lecture 2012: Regulation of adipogenesis: Toward new therapeutics for metabolic disease Diabetes 2013 62 1774 1782 10.2337/db12-1665366162123704518 Search in Google Scholar

[16] Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab. 2007; 293: E444–E552. NedergaardJ BengtssonT CannonB Unexpected evidence for active brown adipose tissue in adult humans Am J Physiol Endocrinol Metab 2007 293 E444 E552 10.1152/ajpendo.00691.200617473055 Search in Google Scholar

[17] van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009; 360: 1500–1508. van Marken LichtenbeltWD VanhommerigJW SmuldersNM DrossaertsJM KemerinkGJ BouvyND SchrauwenP TeuleGJ Cold-activated brown adipose tissue in healthy men N Engl J Med 2009 360 1500 1508 10.1056/NEJMoa080871819357405 Search in Google Scholar

[18] Petrovic N, Walden TB, Shabalina IG, Timmons JA, Cannon B, Nedergaard J. Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J Biol Chem. 2010; 285: 7153–7164. PetrovicN WaldenTB ShabalinaIG TimmonsJA CannonB NedergaardJ Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes J Biol Chem 2010 285 7153 7164 10.1074/jbc.M109.053942284416520028987 Search in Google Scholar

[19] Chen JQ, Huang YY, Gusdon AM, Qu S. Irisin: A new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015; 14: 2. ChenJQ HuangYY GusdonAM QuS Irisin: A new molecular marker and target in metabolic disorder Lipids Health Dis 2015 14 2 10.1186/1476-511X-14-2441726425588692 Search in Google Scholar

[20] Taszarek A, Kaczmarkiewicz A, Miazgowski T. Nadciśnienie i inne choroby metaboliczne - czy krążąca iryzyna ma znaczenie? Nadciśnienie Tętnicze w Praktyce. 2016; 20: 5–10. TaszarekA KaczmarkiewiczA MiazgowskiT Nadciśnienie i inne choroby metaboliczne - czy krążąca iryzyna ma znaczenie? Nadciśnienie Tętnicze w Praktyce 2016 20 5 10 Search in Google Scholar

[21] Vaughan RA, Gannon NP, Barberena MA, Garcia-Smith R, Bisoffi M, Mermier CM, Conn CA, Trujillo KA. Characterization of the metabolic effects of irisin on skeletal muscle in vitro. Diabetes Obes Metab. 2014; 16: 711–718. VaughanRA GannonNP BarberenaMA Garcia-SmithR BisoffiM MermierCM ConnCA TrujilloKA Characterization of the metabolic effects of irisin on skeletal muscle in vitro Diabetes Obes Metab 2014 16 711 718 10.1111/dom.1226824476050 Search in Google Scholar

[22] Huh JY, Dincer F, Mesfum E, Mantzoros CS. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. Int J Obes (Lond). 2014; 38: 1538–1544. HuhJY DincerF MesfumE MantzorosCS Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans Int J Obes (Lond) 2014 38 1538 1544 10.1038/ijo.2014.4224614098 Search in Google Scholar

[23] Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, Mantzoros CS. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017; 13: 324–337. PerakakisN TriantafyllouGA Fernández-RealJM HuhJY ParkKH SeufertJ MantzorosCS Physiology and role of irisin in glucose homeostasis Nat Rev Endocrinol 2017 13 324 337 10.1038/nrendo.2016.221587894228211512 Search in Google Scholar

[24] Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity - correlation with body mass index. Peptides. 2013; 39: 125–130. StengelA HofmannT Goebel-StengelM ElbeltU KobeltP KlappBF Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity - correlation with body mass index Peptides 2013 39 125 130 10.1016/j.peptides.2012.11.01423219488 Search in Google Scholar

[25] Crujeiras AB, Zulet MA, Lopez-Legarrea P, de la Iglesia R, Pardo M, Carreira MC, Martínez JA, Casanueva FF. Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism. 2014; 63: 520–531. CrujeirasAB ZuletMA Lopez-LegarreaP de la IglesiaR PardoM CarreiraMC MartínezJA CasanuevaFF Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients Metabolism 2014 63 520 531 10.1016/j.metabol.2013.12.00724439241 Search in Google Scholar

[26] Ma J, Chen K. The role of Irisin in multiorgan protection. Mol Biol Rep. 2021; 48: 763–772. MaJ ChenK The role of Irisin in multiorgan protection Mol Biol Rep 2021 48 763 772 10.1007/s11033-020-06067-133389537 Search in Google Scholar

[27] Gannon NP, Vaughan RA, Garcia-Smith R, Bisoffi M, Trujillo KA. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer. 2015; 136: E197–E202. GannonNP VaughanRA Garcia-SmithR BisoffiM TrujilloKA Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro Int J Cancer 2015 136 E197 E202 10.1002/ijc.2914225124080 Search in Google Scholar

[28] Kong G, Jiang Y, Sun X, Cao Z, Zhang G, Zhao Z, Zhao Y, Yu Q, Cheng G. Irisin reverses the IL-6 induced epithelial-mesenchymal transition in osteosarcoma cell migration and invasion through the STAT3/Snail signaling pathway. Oncol Rep. 2019; 38: 2647–2656. KongG JiangY SunX CaoZ ZhangG ZhaoZ ZhaoY YuQ ChengG Irisin reverses the IL-6 induced epithelial-mesenchymal transition in osteosarcoma cell migration and invasion through the STAT3/Snail signaling pathway Oncol Rep 2019 38 2647 2656 10.3892/or.2017.5973578001729048621 Search in Google Scholar

[29] Liu J, Song N, Huang Y, Chen Y. Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Sci Rep. 2018; 8: 15247. LiuJ SongN HuangY ChenY Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway Sci Rep 2018 8 15247 10.1038/s41598-018-33229-w618906130323244 Search in Google Scholar

[30] Shao L, Li H, Chen J, Song H, Zhang Y, Wu F, Wang W, Zhang W, Wang F, Li H, Tang D. Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 2017; 485: 598–605. ShaoL LiH ChenJ SongH ZhangY WuF WangW ZhangW WangF LiH TangD Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition Biochem Biophys Res Commun 2017 485 598 605 10.1016/j.bbrc.2016.12.08427986567 Search in Google Scholar

[31] Tekin S, Erden Y, Sandal S, Yilmaz B. Is irisin an anticarcinogenic peptide? Med Sci. 2015; 4: 2172–2180. TekinS ErdenY SandalS YilmazB Is irisin an anticarcinogenic peptide? Med Sci 2015 4 2172 2180 10.5455/medscience.2014.03.8210 Search in Google Scholar

[32] Zhang D, Zhang P, Li L, Tang N, Huang F, Kong X, Tan X, Shi G. Irisin functions to inhibit malignant growth of human pancreatic cancer cells via downregulation of the PI3K/AKT signaling pathway. Onco Targets Ther. 2019; 12: 7243–7249. ZhangD ZhangP LiL TangN HuangF KongX TanX ShiG Irisin functions to inhibit malignant growth of human pancreatic cancer cells via downregulation of the PI3K/AKT signaling pathway Onco Targets Ther 2019 12 7243 7249 10.2147/OTT.S214260673250731564907 Search in Google Scholar

[33] Shi G, Tang N, Qiu J, Zhang D, Huang F, Cheng Y, Ding K, Li W, Zhang P, Tan X. Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2017; 493: 585–591. ShiG TangN QiuJ ZhangD HuangF ChengY DingK LiW ZhangP TanX Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma Biochem Biophys Res Commun 2017 493 585 591 10.1016/j.bbrc.2017.08.14828867187 Search in Google Scholar

[34] Moon HS, Mantzoros CS. Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism. 2014; 63: 188–193. MoonHS MantzorosCS Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines Metabolism 2014 63 188 193 10.1016/j.metabol.2013.10.00524268368 Search in Google Scholar

[35] Kuloğlu T, Artaş G, Yardim M, Sahin I, Aydin Y, Beyoğlu N, Özercan İH, Yalcin MH, Ugur K, Aydin S. Immunostaining characteristics of irisin in benign and malignant renal cancers. Biotech Histochem. 2019; 94: 435–441. KuloğluT ArtaşG YardimM SahinI AydinY BeyoğluN ÖzercanİH YalcinMH UgurK AydinS Immunostaining characteristics of irisin in benign and malignant renal cancers Biotech Histochem 2019 94 435 441 10.1080/10520295.2019.158699830896263 Search in Google Scholar

[36] Ugur K, Aydin S, Kuloglu T, Artas G, Kocdor MA, Sahin İ, Yardim M, Ozercan İH. Comparison of irisin hormone expression between thyroid cancer tissues and oncocytic variant cells. Cancer Manag Res. 2019; 11: 2595–2603. UgurK AydinS KulogluT ArtasG KocdorMA Sahinİ YardimM OzercanİH Comparison of irisin hormone expression between thyroid cancer tissues and oncocytic variant cells Cancer Manag Res 2019 11 2595 2603 10.2147/CMAR.S201979649789631114326 Search in Google Scholar

[37] Nowinska K, Jablonska K, Pawelczyk K, Piotrowska A, Partynska A, Gomulkiewicz A, Ciesielska U, Katnik E, Grzegrzolka J, Glatzel-Plucinska N, et al. Expression of irisin/FNDC5 in cancer cells and stromal fibroblasts of non-small cell lung cancer. Cancers. 2019; 11: 1538. NowinskaK JablonskaK PawelczykK PiotrowskaA PartynskaA GomulkiewiczA CiesielskaU KatnikE GrzegrzolkaJ Glatzel-PlucinskaN Expression of irisin/FNDC5 in cancer cells and stromal fibroblasts of non-small cell lung cancer Cancers 2019 11 1538 10.3390/cancers11101538682644231614634 Search in Google Scholar

[38] Provatopoulou X, Georgiou GP, Kalogera E, Kalles V, Matiatou MA, Papapanagiotou I, Sagkriotis A, Zografos GC, Gounaris A. Serum irisin levels are lower in patients with breast cancer: Association with disease diagnosis and tumor characteristics. BMC Cancer. 2015; 15: 898. ProvatopoulouX GeorgiouGP KalogeraE KallesV MatiatouMA PapapanagiotouI SagkriotisA ZografosGC GounarisA Serum irisin levels are lower in patients with breast cancer: Association with disease diagnosis and tumor characteristics BMC Cancer 2015 15 898 10.1186/s12885-015-1898-1464263826560078 Search in Google Scholar

[39] El Khoury D, Maalouf GE. Exercise-induced irisin, the fat browning myokine, as a potential anticancer agent. J Obesity. 2019; 2019: 6561726. El KhouryD MaaloufGE Exercise-induced irisin, the fat browning myokine, as a potential anticancer agent J Obesity 2019 2019 6561726 10.1155/2019/6561726 Search in Google Scholar

[40] Zhang D, Tan X, Tang N, Huang F, Chen Z, Shi G. Review of research on the role of irisin in tumors. Onco Targets Ther. 2020; 13: 4423–4430. ZhangD TanX TangN HuangF ChenZ ShiG Review of research on the role of irisin in tumors Onco Targets Ther 2020 13 4423 4430 10.2147/OTT.S245178724546432547073 Search in Google Scholar

[41] Krajowy Rejestr Nowotworów. http://onkologia.org.pl/nowotwory-zlosliwe-skory/ (16.09.2021) Krajowy Rejestr Nowotworów http://onkologia.org.pl/nowotwory-zlosliwe-skory/ (16.09.2021) Search in Google Scholar

[42] Komorowska O, Szczerkowska-Dobosz A, Purzycka-Bohdan D, Rawicz-Zegrzda D, Dudziak M. Psoriasis as a risk factor of cardiovascular diseases. Przegl Dermatol. 2014; 101: 500–506. KomorowskaO Szczerkowska-DoboszA Purzycka-BohdanD Rawicz-ZegrzdaD DudziakM Psoriasis as a risk factor of cardiovascular diseases Przegl Dermatol 2014 101 500 506 10.5114/dr.2014.46953 Search in Google Scholar

[43] Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012; 26: 3–11. ReichK The concept of psoriasis as a systemic inflammation: implications for disease management J Eur Acad Dermatol Venereol 2012 26 3 11 10.1111/j.1468-3083.2011.04410.x22356630 Search in Google Scholar

[44] Baran A, Myśliwiec H, Kiluk P, Świderska M, Flisiak I. Serum irisin levels in patients with psoriasis. J Dermatolog Treat. 2017; 28: 304–308. BaranA MyśliwiecH KilukP ŚwiderskaM FlisiakI Serum irisin levels in patients with psoriasis J Dermatolog Treat 2017 28 304 308 10.1080/09546634.2016.125432727786588 Search in Google Scholar

[45] Menter A. Recognizing and managing comorbidities and complications in hidradenitis suppurativa. Semin Cutan Med Surg. 2014; 33 (3 Suppl): 54–56. MenterA Recognizing and managing comorbidities and complications in hidradenitis suppurativa Semin Cutan Med Surg 2014 33 3 Suppl 54 56 10.12788/j.sder.009325188459 Search in Google Scholar

[46] Sadowska M, Lesiak A, Narbutt J. Choroby współistniejące z hidradenitis suppurativa. Forum Dermatologicum. 2019; 5: 112–116. SadowskaM LesiakA NarbuttJ Choroby współistniejące z hidradenitis suppurativa Forum Dermatologicum 2019 5 112 116 10.5603/FD.2019.0011 Search in Google Scholar

[47] Özkur E, Erdem Y, Altunay İK, Demir D, Dolu NÇ, Serin E, Cerman AA. Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: A case-control study. An Bras Dermatol. 2020; 95: 708–713. ÖzkurE ErdemY AltunayİK DemirD DoluNÇ SerinE CermanAA Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: A case-control study An Bras Dermatol 2020 95 708 713 10.1016/j.abd.2020.04.009767240233008659 Search in Google Scholar

[48] Crujeiras AB, Pardo M, Arturo RR, Navas-Carretero S, Zulet MA, Martínez JA, Casanueva FF. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Hum Biol. 2014; 26: 198–207. CrujeirasAB PardoM ArturoRR Navas-CarreteroS ZuletMA MartínezJA CasanuevaFF Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women Am J Hum Biol 2014 26 198 207 10.1002/ajhb.2249324375850 Search in Google Scholar

[49] Mustafa AI, El-Shimi OS. Serum irisin: A prognostic marker for severe acne vulgaris. J Cosmet Dermatol. 2018; 17: 931–934 MustafaAI El-ShimiOS Serum irisin: A prognostic marker for severe acne vulgaris J Cosmet Dermatol 2018 17 931 934 10.1111/jocd.1275330238599 Search in Google Scholar

[50] Álvarez-Villalobos NA, Rodríguez-Gutiérrez R, González-Saldivar G, Sánchez-García A, Gómez-Flores M, Quintanilla-Sánchez C, Treviño-Álvarez AM, Mancillas-Adame LG, González-González JG. Acanthosis nigricans in middle-age adults: A highly prevalent and specific clinical sign of insulin resistance. Int J Clin Pract. 2020; 74: e13453. Álvarez-VillalobosNA Rodríguez-GutiérrezR González-SaldivarG Sánchez-GarcíaA Gómez-FloresM Quintanilla-SánchezC Treviño-ÁlvarezAM Mancillas-AdameLG González-GonzálezJG Acanthosis nigricans in middle-age adults: A highly prevalent and specific clinical sign of insulin resistance Int J Clin Pract 2020 74 e13453 10.1111/ijcp.1345331769902 Search in Google Scholar

[51] Chen JQ, Fang LJ, Song KX, Wang XC, Huang YY, Chai SY, Bu L, Qu S. Serum irisin level is higher and related with insulin in acanthosis nigricans-related obesity. Exp Clin Endocrinol Diabetes. 2016; 124: 203–207. ChenJQ FangLJ SongKX WangXC HuangYY ChaiSY BuL QuS Serum irisin level is higher and related with insulin in acanthosis nigricans-related obesity Exp Clin Endocrinol Diabetes 2016 124 203 207 10.1055/s-0035-156506026588491 Search in Google Scholar